The Welsh Government has agreed a deal with Vertex Pharmaceuticals to give access to the triple combination therapy, Kaftrio, to people with cystic fibrosis (CF) living in Wales on the day the drug receives its European licence.
Cystic fibrosis community in Wales still waiting for access to ivacaftor (Kalydeco®) despite Welsh Government’s agreement to provide the life-changing drug.
A group of singers living with cystic fibrosis (CF) have brought their voices together for a new charity album ‘Stand Together’ along with 11 other choirs ‘with purpose’.
Drug manufacturer Vertex has submitted a proposal to NHS England for access to its current and future CF treatments. The offer, described by Vertex as a ‘portfolio approach’, is similar to that adopted in the Republic of Ireland, and covers not just Orkambi but also future drugs in the pipeline – including new combination therapy Symdeko (tezacaftor/ivacaftor).
Following a request from the Cystic Fibrosis Trust, Orkambi manufacturer Vertex has issued a statement on proposals to increase access to Orkambi and other pipeline drugs, and outlined the next steps for the four UK nations.
Following a meeting with Orkambi manufacturer Vertex on Monday, David Ramsden, the Cystic Fibrosis Trust’s Chief Executive, has issued a statement demanding action and backing a community-led petition to the Government.
As Vertex announces trials for new treatments that could benefit more than 90% of people with cystic fibrosis (CF) in the UK, Dr Belinda Cupid, Senior Impact Adviser at the Trust, takes a closer look.
Today Vertex Pharmaceuticals has announced that the European Medicines Agency (EMA) has validated a marketing-authorisation application for the triple combination Trikafta (elexacaftor, tezacaftor and ivacaftor), meaning that the EMA will carry out a scientific assessment of the application and make a recommendation on whether the medicine should be marketed within the EU or not.
